Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSilo Pharma Inc

Silo Pharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.33 USD 0.04 ( 3.10%)
Last update at 2026-11-06T21:00:00Z
VOLUME
21170
Market Cap
3.40M

Momentum Score

…

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.25
Low
1.36
High
52 Week Price Range
1.91
Low
15.15
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Silo Pharma Inc. is a development-stage biotechnology company focused on therapeutics for neuropsychiatric and neurological disorders. Major long-term growth drivers include clinical-trial progress, regulatory milestones and strategic collaborations that could support eventual commercialization. Investors may find it attractive for exposure to early-stage CNS drug development and the potential for value inflection from positive clinical readouts.

Key investment risks include high clinical and regulatory failure risk, potential dilution from future financing needs and competitive pressures in the CNS therapeutics landscape.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.29
Dividend Yield
-
Revenue TTM
0.05M
Revenue Per Share
0.06
Gross Profit TTM
-0.01M
Debt / Equity
-
ROE
-91.23%
Net Debt
-4.75M
ROCE
-60.25%
Diluted EPS TTM
-3.51

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -4.23M -4.39M -3.63M -3.91M 4.18M
Net income -4.23M -4.39M -3.70M -3.91M 3.90M
Selling general administrative 2.15M 2.40M 3.08M 2.43M 2.27M
Selling and marketing expenses - - 1.34M -1.27M -
Gross profit -0.81M 0.07M 0.07M 0.07M 0.07M
Reconciled depreciation 0.01M 0.01M 0.00M - -
Ebit -4.19M -4.39M -3.86M -3.65M -2.74M
Ebitda -4.18M -4.38M -3.63M -3.58M -2.89M
Depreciation and amortization 0.01M 0.01M - 0.07M -0.15M
Operating income -4.28M -4.71M -3.86M -3.65M -2.74M
Other operating expenses 4.35M 4.78M 3.93M 3.72M 2.96M
Interest expense 0.04M 0.01M 0.00M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.02M
Interest income 0.19M 0.33M 0.36M 0.07M 0.00M
Net interest income 0.16M 0.33M 0.35M 0.07M -0.00M
Income tax expense - - 0.07M 0.00M 0.02M
Total revenue 0.07M 0.07M 0.07M 0.07M 0.07M
Total operating expenses 3.47M 4.77M 3.92M 3.71M 2.96M
Cost of revenue 0.89M 0.01M 0.01M 0.01M 0.01M
Total other income expense net 0.05M 0.31M 0.22M -0.26M 6.93M
Discontinued operations - - - - -0.25M
Net income from continuing ops -4.23M -4.39M -4.24M -3.91M 4.16M
Net income applicable to common shares - - - - 2.50M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7.61M 7.41M 7.75M 11.64M 10.49M
Intangible assets 0.22M 0.24M - - -
Other current assets 0.53M 0.03M 0.02M 0.14M 0.15M
Total liab 1.30M 2.38M 1.57M 1.30M 1.43M
Total stockholder equity 6.31M 5.03M 6.18M 10.34M 9.06M
Deferred long term liab - - - 0.06M 0.02M
Other current liab - - 0.70M 0.36M 0.42M
Common stock 0.00M 0.00M 0.00M 0.00M 0.01M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.01M
Retained earnings -19.49M -15.26M -10.87M -7.17M -3.26M
Other liab - - - - 0.94M
Other assets - - 0.00M - 0.09M
Cash 4.75M 3.91M 3.52M 11.37M 9.84M
Total current liabilities 0.65M 1.66M 0.78M 0.44M 0.49M
Current deferred revenue 0.07M 0.07M 0.07M 0.07M 0.07M
Net debt -4.75M -3.91M -3.52M -11.37M -9.84M
Short term debt - - 0.70M -0.36M -0.42M
Other stockholder equity 25.79M 20.30M 17.05M 17.51M 12.31M
Total current assets 7.39M 7.11M 7.68M 11.57M 10.40M
Net tangible assets - - - - 9.06M
Short term investments 2.11M 3.17M 4.14M 0.00M 0.42M
Net receivables - - - 0.07M 0.06M
Inventory - - - - -0.06M
Accounts payable 0.58M 1.58M 0.70M 0.36M 0.42M
Accumulated other comprehensive income 0.01M 0.00M -0.01M - -
Non currrent assets other - 0.06M 0.06M 0.07M 0.09M
Non current assets total 0.22M 0.30M 0.06M 0.07M 0.09M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 1.22M 0.97M -8.58M 0.09M 7.02M
Change to liabilities - - - - 0.77M
Total cashflows from investing activities 0.64M 0.97M -4.15M - 7.19M
Total cash from financing activities 4.86M 3.24M -0.47M 4.94M 3.79M
Change to operating activities - - - - -0.04M
Net income -4.23M -4.39M -3.70M -3.91M 3.90M
Change in cash 0.84M 0.38M -7.84M 1.53M 8.71M
Begin period cash flow 3.91M 3.52M 11.37M 9.84M 1.13M
End period cash flow 4.75M 3.91M 3.52M 11.37M 9.84M
Total cash from operating activities -4.66M -3.83M -3.22M -3.50M -2.28M
Issuance of capital stock 3.73M 3.41M 0.00M 4.94M 3.79M
Depreciation 0.01M 0.01M 0.09M - 0.11M
Other cashflows from investing activities -0.57M - - - 0.17M
Change to inventory - - -0.34M - -
Change to account receivables - - -0.00M - -
Sale purchase of stock 0.00M -0.17M -0.47M - -
Other cashflows from financing activities - 0.00M -0.47M 0.09M 7.19M
Change to netincome - - - - -6.91M
Capital expenditures 0.57M 0.00M 0.00M 0.00M 0.00M
Change in working capital -1.18M 0.55M 0.30M -0.08M 0.73M
Stock based compensation 0.12M 0.00M 0.01M 0.16M 0.19M
Other non cash items 0.62M 0.00M 0.16M 0.33M -7.10M
Free cash flow -4.66M -3.83M -3.22M -3.50M -2.28M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SILO
Silo Pharma Inc		 0.04
3.10%		 1.33 - - 62.90 0.74 6.38 0.56
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Silo Pharma Inc

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

677 North Washington Boulevard, Sarasota, FL, United States, 34236

718 400 9031

https://silopharma.com

3

Name Title Year Born
Mr. Eric Weisblum Chairman, Pres & CEO 1970
Mr. Daniel E. Ryweck Chief Financial Officer 1965
Dr. James S. Kuo M.B.A., M.D. VP of R&D 1965
Mr. Eric Weisblum Chairman, President & CEO 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…